Pelthos Doses First Patient in Phase 1b/2a Trial for Eye Pain Drug CT2000
Event summary
- Pelthos Therapeutics dosed the first patient in a Phase 1b/2a trial for CT2000, targeting eye pain associated with dry eye disease.
- CT2000 is a NaV1.7 inhibitor developed by subsidiary Channel Therapeutics, focusing on acute and chronic ocular pain.
- The adaptive trial design includes a Phase 1 ascending dose study and a Phase 2a 28-day dosing period, with results expected by year-end 2026.
- Pre-clinical studies in 2025 showed CT2000 met predefined endpoints in animal models for acute and chronic ocular pain.
The big picture
Pelthos Therapeutics is advancing its pipeline beyond its commercial-stage infectious disease products, targeting the underserved eye pain market. The Phase 1b/2a trial of CT2000 represents a strategic pivot toward pain management, leveraging NaV1.7 inhibition—a mechanism with broad potential across various pain indications. The global chronic ocular pain market's projected growth to $5.3 billion by 2032 underscores the significance of this development.
What we're watching
- Clinical Efficacy
- Whether CT2000 demonstrates sufficient safety and efficacy in human trials to justify further development.
- Market Potential
- The pace at which Pelthos can capitalize on the $5.3 billion chronic ocular pain market by 2032.
- Pipeline Expansion
- How the success of CT2000 could influence Pelthos' strategy in expanding its pain management portfolio.
Related topics